2KLC

NMR solution structure of human ubiquitin-like domain of ubiquilin 1, Northeast Structural Genomics Consortium (NESG) target HT5A

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D HNCO	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
2	3D HNCA	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
3	3D CBCA(CO)NH	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
4	3D HCCH-TOCSY	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
5	3D HCCH-TOCSY	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
6	3D 1H-15N NOESY	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
7	3D 1H-13C NOESY	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
8	3D 1H-13C_arom NOESY	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
9	2D 1H-15 HSQC (IPAP)	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
10	2D 1H-15N HSQC	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
11	2D 1H-13C Constant Time HSQC	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
12	3D HBHA(CO)NH	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298
13	3D HNCO (IPAP)	0.5 mM [U-13C; U-15N] ubiquilin 1, 10 mM TRIS, 300 mM sodium chloride (NaCl), 0.01 % sodium azide (NaN3), 1 x inhibitor cocktail (roche), 1 mM benzamidine, 10 uM ZnSO4, 10 mM DTT, 10 % D20, 90 % H20	90% H2O/10% D2O	300	7.0	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	800
2	Bruker	AVANCE	600

NMR Refinement
Method	Details	Software
restrained molecular dynamics		Sparky

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	peak picking	Sparky	3.106	Goddard
2	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	chemical shift assignment	FMC		Lemak, Steren, Llinas & Arrowsmith
4	data analysis	TALOS	2003.027.13.05	Cornilescu, Delaglio and Bax
5	structure solution	CYANA	2.1	Guntert, Mumenthaler and Wuthrich
6	refinement	CNSSOLVE	1.1	Brunger, Adams, Clore, Gros, Nilges and Read
7	collection	TopSpin		Bruker Biospin
8	validation	PSVS	1.3	Bhattacharya and Montelione

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.